Hematopoietic and Lymphoid Neoplasm Project. Acknowledgments American College of Surgeons (ACOS) Commission on Cancer (COC) Canadian Cancer Registries.

Slides:



Advertisements
Similar presentations
Instructions and Reporting Requirements Appendix A Electronic Reporting For Dermatology Physician Practices March 2014 North Carolina Central Cancer Registry.
Advertisements

Instructions and Reporting Requirements Module 3 Electronic Reporting For Facilities March 2014 North Carolina Central Cancer Registry State Center for.
Instructions and Reporting Requirements Module 11 Electronic Reporting For Urology Physician Practices May 2013 North Carolina Central Cancer Registry.
Instructions and Reporting Requirements Module 2 Electronic Reporting For Facilities March 2014 North Carolina Central Cancer Registry State Center for.
1 Renal Pelvis, Ureter, Bladder and Other Urinary.
Hematopoietic Database and Manual
Hematopoietic and Lymphoid Neoplasm Project. Primary Site and Histology Rules Steven Peace, BS, CTR Westat October 2009.
Cancer Registry Coding Changes for 2014 Presented by the Kentucky Cancer Registry February, 2014.
2010 Hematopoietic and Lymphoid Neoplasm Project Issues, Timing and Transformations.
2010 Hematopoietic and Lymphoid Neoplasm Project Maneuvering the Hemato DB and Rules.
Hematopoietic and Lymphoid Neoplasm Project. Primary Site and Histology Rules Peggy Adamo, RHIT, CTR NCI SEER October 2009.
How are cancer statistics kept up to date?.  Example:  Dx stage II colon cancer  Cancer has metastasized to the liver – 2009  How does the.
Hematopoietic and Lymphoid Neoplasm Project. Background Peggy Adamo, RHIT, CTR NCI SEER September 2009.
A Joint Project of the FCRA/ FCDS Task Force.  Joyce Allan, MPh, CTR  Task Force Co-chair  FCRA/ FCDS Task Force.
1 LUNG. 2 Equivalent Terms, Def, Charts, Tables, Illustrations.
TRANSFORMING THE CHILDHOOD CANCER SURVIVOR EXPERIENCE Additional Material.
1 MP/H Coding Rules General Instructions MP/H Task Force Multiple Primary Rules Histology Coding Rules 2007.
2010 Hematopoietic and Lymphoid Neoplasm Project Registry Operations and the SEER Program.
Kentucky Cancer Registry Spring training, 2010 H EMATOPOIETIC AND L YMPHOID N EOPLASM P ROJECT.
Putting the Puzzle Together: Breast Collaborative Staging Melissa Riddle, RHIT, CTR October 6, 2012.
Hematopoietic and Lymphoid Neoplasm Project. Acknowledgments American College of Surgeons (ACOS) Commission on Cancer (COC) Canadian Cancer Registries.
Hematopoietic and Lymphoid Neoplasm Project 1. Acknowledgments American College of Surgeons (ACOS) Commission on Cancer (COC) Canadian Cancer Registries.
Head and Neck MP/H Task Force Multiple Primary Rules
Cancer Registry Update St. Vincent’s Clay NEFHIMA September 10, 2015.
Data Quality Toolbox for Registrars MCSS Workshop December 9, 2003 Elaine Collins.
Timeliness of Cancer Registry Reporting Ali Johnson, CTR Vermont Cancer Registry Vermont Explor Annual Data Meeting May 1, 2006.
1 Myeloma Plasma Cell Disorders (Schema Name: MyelomaPlasmaCellDisorder) V0203.
CASEFINDING Debra W. Christie, MBA, RHIA, CTR, CCRP Director, Cancer Research & Data Center University of Mississippi Medical Center.
1 Head and Neck. 2 Equivalent Terms, Definitions, Charts, Tables and Illustrations Primary site –Do not code biopsy site.
What’s the Diff? Sue C. Vest, CTR Missouri Cancer Registry This project was supported in part by a cooperative agreement between the Centers for Disease.
KCR SPRING TRAINING 2014 New ICD-O-3 Terminology.
2015 CHANGES IN REPORTING REQUIREMENTS AND CANCER CODING INSTRUCTIONS KENTUCKY CANCER REGISTRY SPRING TRAINING 2015 PRESENTED BY FRANCES ROSS.
Hematopoietic and Lymphoid Neoplasm Project. Acknowledgments American College of Surgeons (ACOS) Commission on Cancer (COC) Canadian Cancer Registries.
Kentucky Cancer Registry Abstractor’s Training, March, 2012 H EMATOPOIETIC AND L YMPHOID N EOPLASM C ODING ( PER 2010 RULES )
Agency/Standard Setter Updates OSCaR Fall Educational Workshop Claudia Cooksie, RHIT,CTR October 9, 2015 Portland, Oregon.
PUBLIC HEALTH DIVISION Oregon State Cancer Registry Abstracting Hematologic Malignancies Stepping Up Your Game LeeLa Coleman, CTR Cancer Data Consultant.
KCR 2014 Spring Training CHANGES IN CODING GRADE.
New Data Items MP/H Task Force Multiple Primary Rules Histology Coding Rules 2007.
Data quality of leukaemia experiences in the Netherlands
2010 Hematopoietic and Lymphoid Neoplasm Project Training, Tools and Resources.
2010 Hematopoietic and Lymphoid Neoplasms
ICD-9-CM and ICD-10 Updates and U.S. Adoption of ICD-10-CM Coding Standard: Major Changes in Health Information Coding Practice and Implications for Cancer.
CSv2 for the Hematopoietic Neoplasms 1. 2 This includes five schemas …. Hematopoietic, Reticuloendothelial, Immunopro-liferative and Myeloproliferative.
BY FRANCES ROSS, CTR PRESENTED AT THE NAACCR ANNUAL CONFERENCE JUNE, 2008 Record Consolidation Test with the 2007 Multiple Primary/Histology Rules.
APHA Annual Meeting November 7, 2007 Karla Armenti, ScD* Division of Public Health Services New Hampshire Department of Health and Human Services S Cherala*,
Integrating Central and Hospital Registries To Improve Timeliness and Data Quality (The Central Cancer Registry as a Hub for Data Exchange) David Rousseau,
1 Virginia Cancer Registrars Association and Virginia Cancer Registry Annual Meeting October 3, 2007.
Gary M. Levin, BA, CTR Florida Cancer Data System NAACCR 2008 Annual Conference 2007 Multiple Primary Rules: Impact on Tumor Counts.
1. Multiple Primary and Histology Rules 101 Format of MP/H Materials.
Jennifer Ruhl, BBA, RHIT, CTR Public Health Analyst NCI SEER An innovative approach to improve the quality of data collection for hematopoietic diseases.
Electronic CAP Cancer Checklists and Cancer Registries – A Pilot Project 2009 NAACCR Conference Ken Gerlach, MPH, CTR Castine Verrill, MS, CTR CDC-National.
Virginia Cancer Registry 2007 Update Fredericksburg, VA October 3, 2007.
Virginia Cancer Registrars Association and Virginia Cancer Registry Annual Meeting October 3, 2007.
2016 Edits.
Kentucky Cancer Registry
SNOMED CT® in Surgical Pathology and Cancer Registry Work
Optimizing your EMR in the Cancer Registry
Cancer Reporting Changes for 2017 and 2018
Population-Based Cancer Registries in the United States:
Quality Control Abstract Visual Review Process
Tumor Grade.
SEER Case Consolidation Study: Design & Objective
Automated Consolidation of Collaborative Stage Data Items
Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual
2018 Updates to ICD-O-3 Histology Coding
North Carolina Central Cancer Registry Electronic Reporting For
department of health and human resources
Martin Whiteside, DC, PhD, MSPH Director, Tennessee Cancer Registry
Text Mining for Data Quality Analysis of Melanoma Tumor Depth
Presentation transcript:

Hematopoietic and Lymphoid Neoplasm Project

Acknowledgments American College of Surgeons (ACOS) Commission on Cancer (COC) Canadian Cancer Registries (CCR) National Cancer Registrars Association (NCRA) National Program of Cancer Registries (NPCR) of the Centers for Disease Control (CDC) North American Association of Central Cancer Registries (NAACCR) 2

With Special Thanks to Graca Dores, MD Charles Platz, MD Amy Blum, RHIT, CTR The Hematopoietic Working Group 3

Grade of Tumor Rules Peggy Adamo, RHIT, CTR NCI SEER October 2009

The Grade Field NAACCR Item #440: “Grade” Immunophenotype Designation for Lymphomas and Leukemias 5

Grade of Tumor Rules Note 1:Use the Grade of Tumor Rules (G1- G11) to assign the correct code in grade field Note 2:Do not use Table 13 on pages of ICD-O-3 to determine grade 6

Rule G1 Code cell type not determined, not stated, not applicable (code 9) for the following myeloproliferative neoplasms, myeloproliferative/myelodysplastic syndromes, myelodysplastic syndrome, histiocytic and dendritic cell neoplasms 7

Rule G1 Continued /39759/39962/39983/3 9741/39875/39963/39985/3 9742/39876/39964/39986/3 9751/39945/39975/39989/3 9755/39946/39980/39991/3 9757/39950/39982/39992/3 9758/39961/39982/3

Rule G1 Notes Note 1:These neoplasms do not have a specific codable phenotype Note 2:See Tables B1, B3, B4, and B11 in Appendix B for neoplasm terms and codes 9

Appendix B WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues Histology Lineage Table B1: Myeloproliferative Neoplasms Table B3: Myelodysplastic / Myeloproliferative Neoplasms Table B4: Myelodysplastic Syndromes Table B11: Histiocytic and Dendritic Cell Neoplasms 10

Rule G2 Use statements from any part of the medical record including, but not limited to Pathology report OR History and physical OR Consultation OR Final diagnosis OR Face sheet 11

Rule G3 Use codes 5, 6, 7, 8, and/or 9 only -- even if there is a statement giving the cell type in the medical record 12

Rule G3 Notes Note 1:Do not code descriptions “low grade,” “intermediate grade,” or “high grade” in the Tumor Grade field. These terms refer to the Working Formulation categories of lymphoma diagnosis Note 2:Do not code the descriptions “Grade 1,” “Grade 2,” or “Grade 3” in the Tumor Grade field. These grades represent histology types of lymphoma rather than differentiation 13

Rule G4 Code T-cell (code 5) for the following neoplasms; T-cell is part of the neoplasm name or the neoplasm is of T-cell origin 14

Rule G4 Continued 9701/39716/39827/3 9702/39717/39831/3 9705/39718/39834/3 9708/39724/39837/3 9709/39725/3 9714/3*9726/3 15 *(unless pathologist specifically designates as B-cell)

Rule G4 Note 1 Record T-cell even though it is not mentioned as a specific phenotype in the pathology or other test report(s). Frequently physicians do not mention T- cell phenotype because they know the phenotype or they understand that the phenotype is inherent in the disease classification/name 16

Rule G4 Note 2 When the medical record or pathology report contains one of these terms with a different phenotype (B-cell, null-cell, or NK-cell) check with the pathologist to determine whether the disease name is correctly recorded. It is possible that the mention of a different phenotype may be the result of the pathologist using a different disease classification 17

Rule G5 Code T-cell (code 5) when the neoplasm is identified as T-cell, T-cell phenotype, T- precursor, Pre-T, gamma-delta-T, or null-cell T-cell 18

Rule G6 Code B-cell (code 6) for the following B-cell precursor lymphoid neoplasms and the mature B-cell neoplasms 19

Rule G6 Continued 9591/39679/39691/39732/39813/39833/3 9596/39680/39695/39734/39814/39836/3 9597/39684/39698/39737/39815/39940/3 9670/39687/39699/39738/39816/3 9671/39688/39712/39762/39817/3 9673/39689/39728/39811/39818/3 9678/39690/39731/39812/39823/3 20

G6 Note 1 Record B-cell even though it is not mentioned as a specific phenotype in the pathology or other test report(s). Frequently physicians do not mention B- cell phenotype because they know the phenotype or they understand that the phenotype is inherent in the disease classification/name 21

G6 Note 2 When the medical record or pathology report contains one of these terms with a different phenotype (T-cell, null-cell, or NK-cell) check with the pathologist to determine whether the disease name is correctly recorded. It is possible that the mention of a different phenotype may be the result of the pathologist using a different disease classification 22

G6 Note 3 See Tables B7 and B8 in Appendix B 23

Appendix B WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues Histology Lineage Table B7: Precursor Lymphoid Neoplasms Table B8: Mature B-Cell Neoplasms 24

Rule G7 Code B-cell (code 6) when the disease is identified as B-cell, B-cell phenotype, B- precursor, pre-B, or null-cell and B-cell 25

Rule G8 Code Null cell, non-T non-B (code 7) when the disease is described as null cell, non-T non-B, or common cell 26

Rule G9 Code NK-cell (natural killer cell) (code 8) for the following neoplasms; NK-cell is a part of the neoplasm’s name 9719/3 9948/3 27

Rule G9 Note 1 Record NK-cell even though it is not mentioned as a specific phenotype in the pathology or other test report(s). Frequently physicians do not mention NK- cell phenotype because they know the phenotype or they understand that the phenotype is inherent in the disease classification/name 28

Rule G9 Note 2 When the medical record or pathology report contains one of these terms with a different phenotype (B-cell, T-cell, or null-cell) check with the pathologist to determine whether the disease name is correctly recorded. It is possible that the mention of a different phenotype may be the result of the pathologist using a different disease classification 29

Rule G9 Note 3 See Table B8 in Appendix B 30

Appendix B WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues Histology Lineage Table B8: Mature B-Cell Neoplasms 31

Rule G10 Code Natural Killer (NK) cell (code 8) when the disease is described as NK cell, natural killer cell, nasal NK/T-cell lymphoma, or null-cell and NK cell 32

Rule G11 Code cell type not determined, not stated, not applicable (code 9) when There is no statement describing the cell type OR The cell type is described as combined T AND B cell OR The cell type is described as combined B AND NK cell 33

Rule G11 Note There is a new site-specific factor to collect combination cell types for hematopoietic or lymphatic neoplasms in the Collaborative Stage Data Collection System, Version 2 34

Conclusion The new Hematopoietic and Lymphoid Neoplasm Rules go into effect for cases diagnosed January 1, 2010, and after address for questions 35